Bovine Infectious Agents and Cooking-Induced Carcinogens Contribute to Certain Cancers

Article
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this interview we discuss a bovine infectious agent, which may interact with carcinogens that arise during cooking or curing, and play a causative role in certain cancer.

In this interview, Harald zur Hausen, MD, 2008 Nobel Laureate and Professor Emeritus at the German Cancer Research Center in Heidelberg, discusses his epidemiologic work to investigate a bovine infectious agent that may interact with carcinogens arising during the cooking or curing of beef and play a causative role in certain cancers. Dr. zur Hausen also discusses how animal-derived viruses are being increasingly investigated as vectors for immunotherapy and the prevention of a variety of cancers.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content
The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

Tim Cortese
March 11th 2025
Article

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Active Monitoring May Be Safe Vs Surgery in Certain Low-Risk DCIS Populations

Russ Conroy
March 10th 2025
Article

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate Higher Risk of ICANS in Patients With NHL

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate Higher Risk of ICANS in Patients With NHL

Tim Cortese
February 18th 2025
Article

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.